PRS44 Cost Utility Analysis of Omalizumab Therapy for Severe Asthma Patients in Thailand

Value in Health - United Kingdom
doi 10.1016/j.jval.2011.08.1431
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Appropriate Selection for Omalizumab Treatment in Patients With Severe Asthma?

European Clinical Respiratory Journal
2017English

Omalizumab in Patients With Severe Asthma and Persistent Sputum Eosinophilia

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Omalizumab as Add‐on Therapy in a Patient With Severe Asthma and OSA

Respirology Case Reports
PulmonaryRespiratory Medicine
2020English

Omalizumab: A Potential Therapy Option for Allergic Bronchopulmonary Aspergillosis (ABPA) in Asthma Patients

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

A Review of Omalizumab for the Management of Severe Asthma

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2016English

Cost-Utility Analysis of Taxane Therapy

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
1997English

Omalizumab and Mepolizumab in the Landscape of Biological Therapy for Severe Asthma in Children: How to Choose?

Italian Journal of Pediatrics
Child HealthPediatricsPerinatology
2019English

A Cost-Utility Analysis of Drug Treatments in Patients With HBeAg-positive Chronic Hepatitis B in Thailand

BMC Health Services Research
Health Policy
2014English

Utility of Impulse Oscillometry in Patients With Moderate to Severe Persistent Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy